Delandistrogene Moxeparvovec

4 trials 1 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

1 Completed trials

2 Sponsors

6 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 2 Phase II: 1 Phase I (Other): 1

Oversight events:

12 temporary halts 2 corrective measures across 3 trials

View oversight register →

Indications tested

Duchenne muscular dystrophy gene carrier 4 Duchenne muscular dystrophy 3

Sponsors using this IMP

Sarepta Therapeutics Inc. 3 F. Hoffmann-La Roche AG 1

All trials

4 total

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION) Recruiting

2023-505043-39-00 Phase III 4 countries Sarepta Therapeutics Inc.
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulator… Halted

2024-512626-28-00 Phase III 6 countries Sarepta Therapeutics Inc.
Study to assess the safety and expression of RO7494222 (SRP-9001) in participants under the age of 4 with Duchenne muscular dystrophy Halted

2023-509901-57-00 Phase II 5 countries F. Hoffmann-La Roche AG
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion … Ended

2024-512624-11-00 Phase I (Other) 1 country Sarepta Therapeutics Inc.

Showing 1–4 of 4 trials

← All drugs A–Z